The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Firsov K.V.

Vladimirsky Moscow Regional Research Institute, Moscow, Russia

Kotov A.S.

Moskovskiĭ oblastnoĭ nauchno-issledovatel'skiĭ klinicheskiĭ institut im. M.F. Vladimirskogo

Bunak M.S.

Moscow Regional Research and Clinical Institute, Moscow, Russia

Genetic causes of stroke in young patients

Authors:

Firsov K.V., Kotov A.S., Bunak M.S.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(1): 102‑109

DOI: 10.17116/jnevro2019119011102

Views: 1772

Downloaded: 67

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Firsov KV, Kotov AS, Bunak MS. Genetic causes of stroke in young patients. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(1):102‑109. (In Russ.)
https://doi.org/10.17116/jnevro2019119011102

 
МСФ на ЯМ
Close metadata
Recommended articles:
Cere­brolysin as an early add-on to repe­rfusion therapy: hete­rogeneous treatment effect analysis in ischemic stroke patients with varying risk of hemo­rrhagic transformation. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3-2):55-66
Effi­cacy of Mexi­dol in combination with cere­bral reva­scularization in the treatment of ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3-2):67-74
Cognitive impairment in cere­brovascular diseases. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):12-16
Algo­rithms for the diagnosis and treatment of cognitive impairment and dysphagia in stroke patients. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):100-107
Brain-derived neurotrophic factor in the acute and early reco­very period of ischemic stroke: the role of nocturnal hypo­xemia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5-2):72-78
Comparison of the effe­ctiveness of non-immunogenic staphylokinase and alte­plase for intravenous thro­mbolysis in ischemic stroke: analysis of hospital regi­stry data. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7):139-144
Arti­ficial ventilation in patients with stroke: main resu­lts of the Russian multicenter obse­rvational clinical trial RETAS. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(8-2):5-13
The impact of the impairment of social cognitive functions in acute stage of stroke on its functional outcomes. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(8-2):21-25
Possibilities of mirror therapy in cognitive reha­bilitation after stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(8-2):64-71
Dyna­mics of motor and functional diso­rders in the early reco­very period after ischemic stroke. Problems of Balneology, Physiotherapy and Exercise Therapy. 2024;(5):13-22

The paper addresses genetic causes of stroke: MELAS, antiphospholipid syndrome, CADASIL, Fabry disease. The etiology and pathogenesis, symptoms, diagnosis, treatment methods of these diseases are described.

Keywords:

stroke
genetic diseases
young patients
MELAS
antiphospholipid syndrome
Fabry disease
CADASIL
agalsidase alfa
agalsidase beta

Authors:

Firsov K.V.

Vladimirsky Moscow Regional Research Institute, Moscow, Russia

Kotov A.S.

Moskovskiĭ oblastnoĭ nauchno-issledovatel'skiĭ klinicheskiĭ institut im. M.F. Vladimirskogo

Bunak M.S.

Moscow Regional Research and Clinical Institute, Moscow, Russia

List of references:

  1. Kotov SV, Stakhovskaya LV, Isakova EV, Ivanova GE, Shamalov NA, Gerasimenko MYu, Vishnyakova MV, Volchenkova TV, Dersanov SV, Kazanchyan PO, Kiselev AM, Kotov AS, Sidorova OP, Sherman LA. Insul’t: Rukovodstvo dlya vrachej. Guide for physicians. Edited by Stakhovskaya LV, Kotov SV. Moscow; 2014. (In Russ.)
  2. Sandu EA, Kotov AS, Litvinenko MA, Sorokina EK, Isakova EV, Kotov SV. «Risk assessment of stroke» evaluation to identify individuals at risk. Klinicheskaya Gerontologiya (Clinical Gerontology). 2016;22(5-6):10-17. (In Russ.)
  3. Poisson SN, Schardt TQ, Dingman A, Bernard TJ. Etiology and treatment of arterial ischemic stroke in children and young adults. Curr Treat Options Neurol. 2014;16(10):315. https://doi.org/10.1007/s11940-014-0315-4
  4. El-Hattab AW, Emrick LT, Hsu JW, Chanprasert S, Almannai M, Craigen WJ, Jahoor F, Scaglia F. Impaired nitric oxide production in children with MELAS syndrome and the effect of arginine and citrulline supplementation. Mol Genet Metab. 2016;117(4):407-412. https://doi.org/10.1016/j.ymgme.2016.01.010
  5. Kaufmann P, Shungu DC, Sano MC, Jhung S, Engelstad K, Mitsis E, Mao X, Shanske S, Hirano M, DiMauro S, De Vivo DC. Cerebral lactic acidosis correlates with neurological impairment in MELAS. Neurology. 2004;62:1297-1302. https://doi.org/10.1212/01.wnl.0000120557.83907.a8
  6. El-Hattab AW, Adesina AM, Jones J, Scaglia F. MELAS syndrome: Clinical manifestations, pathogenesis, and treatment options. Mol Genet Metab. 2015;116(1-2):4-12. https://doi.org/10.1016/j.ymgme.2015.06.004
  7. Karppa M, Syrajala P, Tolonen U, Majamaa K. Peripheral neuropathy in patients with the 3243A. J Neurol. 2003;250:216-221. https://doi.org/10.1007/s00415-003-0981-8
  8. Iizuka T, Sakai F, Kan S, Suzuki N. Slowly progressive spread of the stroke-like lesions in MELAS. Neurology. 2003;61:1238-1244. https://doi.org/10.1212/01.wnl.0000091888.26232.fe
  9. Lee HN, Eom S, Kim SH, Kang HC, Lee JS, Kim HD, Lee YM. Epilepsy Characteristics and Clinical Outcome in Patients With Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Episodes (MELAS). Pediatr Neurol. 2016;S0887-8994(16):30416-7. https://doi.org/10.1016/j.pediatrneurol.2016.08.016.
  10. Ichikawa H. Higher Brain Dysfunction in Mitochondrial Myopathy, Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS). Brain Nerve. 2016;68(2):151-157. https://doi.org/10.11477/mf.1416200366
  11. Shi YH, Zhao JH, Song JL, Li YJ, Liang K. Analysis on clinical features and functional MRI of mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes. Zhonghua Yi Xue Za Zhi. 2016;96(37):2969-2972. https://doi.org/10.3760/cma.j.issn.0376-2491.2016.37.004
  12. Marie SKN, Goto Y, Passos-Bueno MR, Zatz M, Carvalho AAS, Carvalho M, Levy JA, Palou VB, Campiotto S, Horai S, Nonaka I. A Caucasian family with the 3271 mutation in mitochondrial DNA. Biochem Med Metab Biol. 1994;52:136-139. https://doi.org/10.1006/bmmb.1994.1045
  13. Wang YX, Le WD. Progress in Diagnosing Mitochondrial Myopathy, Encephalopathy, Lactic Acidosis, and Stroke-like Episodes. Chin Med J (Engl). 2015;128(13):1820-1825. https://doi.org/10.4103/0366-6999.159360
  14. Koenig MK, Emrick L, Karaa A, Korson M, Scaglia F, Parikh S, Goldstein A. Recommendations for the Management of Strokelike Episodes in Patients With Mitochondrial Encephalomyopathy, Lactic Acidosis, and Strokelike Episodes. JAMA Neurol. 2016;73(5):591-594. https://doi.org/10.1001/jamaneurol.2015.5072
  15. Finsterer J, Wakil SM. Stroke-like episodes, peri-episodic seizures, and MELAS mutations. Eur J Paediatr Neurol. 2016;20(6):824-829. https://doi.org/10.1016/j.ejpn.2016.08.002
  16. Miyakis S, Lockshin M, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RHWM, De Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyinnopoulos PG, Krilis SA. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295-306. https://doi.org/10.1111/j.1538-7836.2006.01753.x
  17. Khan S. Antiphospholipid syndrome is an important modifiable risk factor of stroke in the young. Ann Indian Acad Neurol. 2015;18(3):359-360. https://doi.org/10.4103/0972-2327.160058
  18. Kalashnikova LA. Neurology of antiphospholipid syndrome. M.: Medicina; 2003. (In Russ.)
  19. Berkun Y, Simchen MJ, Strauss T, Menashcu S, Padeh S, Kenet G. Antiphospholipid antibodies in neonates with stroke — a unique entity or variant of antiphospholipid syndrome? Lupus. 2014;23(10):986-993. https://doi.org/10.1177/0961203314531842
  20. Seifert CL, Kowarik MC, Thürmel K, Berthele A, Prothmann S, Wunderlich S. Rapidly progressive intracranial artery stenosis in primary antiphospholipid syndrome. Ann Clin Transl Neurol. 2015;2(7):780-782. https://doi.org/10.1002/acn3.215
  21. Cervera R, Serrano R, Pons-Estel GJ, Ceberio-Hualde L, Shoenfeld Y, de Ramón E, Buonaiuto V, Jacobsen S, Zeher MM, Tarr T, Tincani A, Taglietti M, Theodossiades G, Nomikou E, Galeazzi M, Bellisai F, Meroni PL, Derksen RH, de Groot PG, Baleva M, Mosca M, Bombardieri S, Houssiau F, Gris JC, Quéré I, Hachulla E, Vasconcelos C, Fernández-Nebro A, Haro M, Amoura Z, Miyara M, Tektonidou M, Espinosa G, Bertolaccini ML, Khamashta MA; Euro-Phospholipid Project Group (European Forum on Antiphospholipid Antibodies). Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis. 2015;74(6):1011-1018. https://doi.org/10.1136/annrheumdis-2013-204838
  22. Islam MA, Alam F, Kamal MA, Wong KK, Sasongko TH, Gan SH. «Non-criteria» neurologic manifestations of antiphospholipid syndrome: A hidden kingdom to be discovered. CNS Neurol Disord Drug Targets. 2016;15(10):1253-1265. https://doi.org/10.2174/1871527315666160920122750
  23. Carecchio M, Cantello R, Comi C. Revisiting the molecular mechanism of neurological manifestations in antiphospholipid syndrome: beyond vascular damage. J Immunol Res. 2014;2014:239398. https://doi.org/10.1155/2014/239398
  24. Pengo V, Bison E, Zoppellaro G, Padayattil Jose S, Denas G, Hoxha A, Ruffatti A, Banzato A. APS — Diagnostics and challenges for the future. Autoimmun Rev. 2016;15(11):1031-1033. https://doi.org/10.1016/j.autrev.2016.07.028
  25. Okuma H, Kitagawa Y, Takagi S. Investigation of antiphosphatidyl-serine antibody and antiphosphatidyl-inositol antibody in ischemic stroke patients. Clin Dev Immunol. 2010;439230. https://doi.org/10.1155/2010/439230
  26. Antiphospholipid Syndrome: Insights and Highlights from the 13th International Congress on Antiphospholipid Antibodies. D. Erkan and S.S. Pierangeli (eds.). New York: Springer Science+Business Media; 2012. https://doi.org/10.1007/978-1-4614-3194-7_17
  27. Arachchillage DR, Machin SJ, Cohen H. Antithrombotic treatment for stroke associated with antiphospholipid antibodies. Expert Rev Hematol. 2014;7(2):169-172. https://doi.org/10.1586/17474086.2014.892413
  28. Kim E, Do T, Peacock K, Takundwa PT. Recommended Therapeutic INR Range for Patients with Antiphospholipid Syndrome on Warfarin Anticoagulation: Is Moderate-Intensity (INR 2.0—3.0) or High-Intensity (INR 3.1 — 4.0) Better for Reducing Risk of Recurrent Thromboembolic Events? Cureus. 2016;8(9):765. https://doi.org/10.7759/cureus.765
  29. Ruiz-Irastorza G, Cuadrado M, Ruiz-Arruza I, Brey R, Crowther M, Derksen R, Erkan D, Krilis S, Machin S, Pengo V, Pierangeli S, Tektonidou M, Khamashta M. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th international congress on antiphospholipid antibodies. Lupus. 2011;20:206-218. https://doi.org/10.1177/0961203310395803
  30. Crowther MA, Ginsberg JS, Julian J, Denburg J, Hirsh J, Douketis J, Laskin C, Fortin P, Anderson D, Kearon C, Clarke A, Geerts W, Forgie M, Green D, Costantini L, Yacura W, Wilson S, Gent M, Kovacs M. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med. 2003;349:1133-1138. https://doi.org/10.1056/nejmoa035241
  31. Kitchens CS, Erkan D, Brandão LR, Hahn S, James A.H., Kulkarni R, Pericak-Vance M, Vance J, Ortel T.L. Thrombotic storm revisited: preliminary diagnostic criteria suggested by the Thrombotic Storm Study Group. Am J Med. 2011;124:290-296. https://doi.org/10.1016/j.amjmed.2010.10.018
  32. Asherson RA, Cervera R, de Groot PG, Erkan D, Boffa M-C, Piette J-C, Khamashta MA, Shoenfeld Y for the Catastrophic Antiphospholipid Syndrome Registry Project Group. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus. 2003;12:530-534. https://doi.org/10.1191/0961203303lu394oa
  33. Bick R, Rice J. Long-term outpatients dalteparin (fragmin) therapy for arterial and venous thrombosis: efficacy and safety — apreliminary report. Clin Appl Thromb Hemost. 1999;5(suppl. 1):67-71. https://doi.org/10.1177/107602969900500112
  34. Al Marzooqi A, Leone A, Al Saleh J, Khamashta M. Current status and future prospects for the treatment of antiphospholipid syndrome. Expert Rev Clin Immunol. 2016;12(9):927-935. https://doi.org/10.1080/1744666X.2016.1178573
  35. Schaefer JK, McBane RD, Black DF, Williams LN, Moder KG, Wysokinski WE. Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients. Thromb Haemost. 2014;112(5):947-950. https://doi.org/10.1160/TH14-03-0272
  36. Krüger T, Floege J. Vitamin K antagonists: beyond bleeding. Semin Dial. 2014;27(1):37-41. https://doi.org/10.1111/sdi.12175
  37. Sugie M, Iizuka N, Shimizu Y, Ichikawa H. Cerebral Venous Thromboembolism in Antiphospholipid Syndrome Successfully Treated with the Combined Use of an Anti-Xa Inhibitor and Corticosteroid. Intern Med. 2015;54(23):3051-3056. https://doi.org/10.2169/internalmedicine.54.5045
  38. Camara-Lemarroy CR, Infante-Valenzuela A, Andrade-Vazquez CJ, Enriquez-Noyola RV, Garcia-Valadez EA, Gongora-Rivera F. Successful intravenous thrombolysis in a patient with antiphospholipid syndrome, acute ischemic stroke and severe thrombocytopenia. Blood Coagul Fibrinolysis. 2016;27(3):354-356. https://doi.org/10.1097/MBC.0000000000000432
  39. Legault KJ, Ugarte A, Crowther MA, Ruiz-Irastorza G. Prevention of Recurrent Thrombosis in Antiphospholipid Syndrome: Different from the General Population? Curr Rheumatol Rep. 2016;18(5):26. https://doi.org/10.1007/s11926-016-0573-0
  40. Ruffatti A, Del Ross T, Ciprian M, Nuzzo M, Rampudda M, Bertero MT, Bergia R, Caramaschi P, Biasi D, Capsoni F, Montaguti L, Ruffini R, Brucato A, Picillo U, Fanelli V, Riccieri V, Piccoli A, Valesini G, Doria G, Meroni PL, Tincani A. Risk factors for a first thrombotic event in antiphospholipid antibody carriers. A multicentre, retrospective follow-up study. Ann Rheum Dis. 2009;68:397-399. https://doi.org/10.1136/ard.2008.096669
  41. Pengo V, Ruffatti A, Legnani C, Testa S, Fierro T, Marongiu F, De Micheli V, Gresele P, Tonello M, Ghirarduzzi A, Bison E, Denas G, Banzato A, Padayattil Jose S, Iliceto S. Incidence of a first thromboembolic event in asymptomatic carriers of high risk antiphospholipid antibody profile: a multicenter prospective study. Blood. 2011;118:4714-4718. https://doi.org/10.1182/blood-2011-03-340232
  42. Tutill JL, Khamashta MA. Management of antiphospholipid syndrome. J Autoimmun. 2009;33(2):92-98. https://doi.org/10.1016/j.jaut.2009.05.002
  43. Baron-Menguy C, Domenga-Denier V, Ghezali L, Faraci FM, Joutel A. Increased Notch3 activity mediates pathological changes in structure of cerebral Arteries. Hypertension. 2017;69(1):60-70. https://doi.org/10.1161/HYPERTENSIONAHA.116.08015
  44. Kang HG, Kim JS. Intracranial arterial disease in CADASIL patients. J Neurol Sci. 2015;359(1-2):347-350. https://doi.org/10.1016/j.jns.2015.11.029
  45. Tan RY, Markus HS. CADASIL: Migraine, Encephalopathy, Stroke and Their Inter-Relationships. PLoS One. 2016;11(6):e0157613. https://doi.org/10.1371/journal.pone.0157613
  46. Pradotto L, Orsi L, Mencarelli M, Caglio M, Lauro D, Milesi A, Di Blasio A, Mauro A. Recurrent transient global amnesia as presenting symptoms of CADASIL. Clin Case Rep. 2016;4(11):1045-1048. https://doi.org/10.1002/ccr3.666
  47. Zhu S, Nahas SJ. CADASIL: Imaging Characteristics and Clinical Correlation. Curr Pain Headache Rep. 2016;20(10):57. https://doi.org/10.1007/s11916-016-0584-6
  48. Joshi S, Yau W, Kermode A. CADASIL mimicking multiple sclerosis: The importance of clinical and MRI red flags. J Clin Neurosci. 2016;5867-5868(16):30202-8. https://doi.org/10.1016/j.jocn.2016.09.025
  49. Samões R, Alves JE, Taipa R, Silva J, Melo Pires M, Pereira-Monteiro JM. CADASIL: MRI may be normal in the fourth decade of life — a case report. Cephalalgia. 2016;36(11):1082-1085. https://doi.org/10.1177/0333102415618613
  50. Tamaki K, Fukae J, Koga K, Nagatoshi A, Ueda A, Ouma S, Ando Y, Tsuboi Y. Skin biopsy is a useful tool for the diagnosis of atypical CADASIL: A Case Report. Brain Nerve. 2015;67(12):1533-1537. https://doi.org/10.11477/mf.1416200
  51. Rutten J. Lesnik Oberstein SAJ. CADASIL. 2000 Mar. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Fong CT, Mefford HC, Smith RJH, Stephens K (ed.). Seattle (WA): University of Washington; 1993-2016.
  52. Khan MT, Murray A, Smith M. Successful Use of Intravenous Tissue Plasminogen Activator as Treatment for a Patient with Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy: a case report and review of literature. J Stroke Cerebrovasc Dis. 2016;25(4):53-57. https://doi.org/10.1016/j.jstrokecerebrovasdis.2015.12.006
  53. Jazi AN, Shebak SS, Tingler WL. Managing Depression in Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL): a case report. Prim Care Companion CNS Disord. 2016;18:4. https://doi.org/10.4088/PCC.15l01919
  54. Karlsson WK, Sørensen CG, Kruuse C. L-arginine and L-NMMA for Assessing Cerebral Endothelial Dysfunction in Ischemic Cerebrovascular Disease: A Systematic Review. Clin Exp Pharmacol Physiol. 2016. https://doi.org/10.1111/1440-1681.12679
  55. Tuttolomondo A, Pecoraro R, Simonetta I, Miceli S, Arnao V, Licata G, Pinto A. Neurological complications of Anderson—Fabry disease. Curr Pharm Des. 2013;19(33):6014-6030. https://doi.org/10.2174/13816128113199990387
  56. Ginsberg L. Nervous system manifestations of Fabry disease: data from FOS — the Fabry outcome survey. In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry Disease: Perspectives from 5 Years of FOS. Oxford: Oxford PharmaGenesis; 2006.
  57. Cormican MT, Paschalis T, Viers A, Alleyne CH Jr. Unusual case of subarachnoid haemorrhage in patient with Fabry’s disease: case report and literature review. BMJ Case Rep. 2012;bcr0220125727. https://doi.org/10.1136/bcr.02.2012.5727
  58. Clavelou P, Besson G. Neurological aspects of Fabry disease. Presse Med. 2007;36(1):65-68.
  59. Firsov KV, Kotov AS. The neurological manifestations of Fabry disease. A review. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2016;116(9):98-105. (In Russ.) https://doi.org/10.17116/jnevro20161169198-105
  60. Shi Q, Chen J, Pongmoragot J, Lanthier S, Saposnik G. Prevalence of Fabry disease in stroke patients--a systematic review and meta-analysis. J Stroke Cerebrovasc Dis. 2014;23(5):985-992. https://doi.org/10.1016/j.jstrokecerebrovasdis.2013.08.010
  61. Viana-Baptista M. Stroke and Fabry disease. J Neurol. 2012;259(6):1019-1028. https://doi.org/10.1007/s00415-011-6278-4
  62. Sivley MD. Fabry disease: a review of ophthalmic and systemic manifestations. Optom Vis Sci. 2013;90(2):63-78. https://doi.org/10.1097/OPX.0b013e31827ec7eb
  63. Sodi A, Ioannidis A, Pitz S. Ophthalmological manifestations of Fabry disease. In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry disease: perspectives from 5 years of FOS. Oxford: Oxford PharmaGenesis; 2006.
  64. Giuseppe P, Daniele R, Rita BM. Cutaneous complications of Anderson-Fabry disease. Curr Pharm Des. 2013;19(33):6031-6036.
  65. Low M, Nicholls K, Tubridy N, Hand P, Velakoulis D, Kiers L, Mitchell P, Becker G. Neurology of Fabry disease. Intern Med J. 2007;37(7):436-447.
  66. Winchester B, Young E. Biochemical and genetic diagnosis of Fabry disease. In: Mehta A, Beck M, Sunder-Plassmann G, ed. Fabry disease: perspectives from 5 years of FOS. Oxford: Oxford Pharma Genesis; 2006.
  67. Fellgiebel A, Albrecht J, Dellani PR, Schermuly I, Stoeter P, Müller MJ. Quantification of brain tissue alterations in Fabry disease using diffusion-tensor imaging. Acta Paediatr. 2007;96(455):33-36. https://doi.org/10.1111/j.1651-2227.2007.00203.x
  68. Low M, Nicholls K, Tubridy N, Hand P, Velakoulis D, Kiers L, Mitchell P, Becker G. Neurology of Fabry disease. Intern Med J. 2007;37(7):436-447.
  69. van der Tol L, Svarstad E, Ortiz A, Tøndel C, Oliveira JP, Vogt L, Waldek S, Hughes DA, Lachmann RH, Terryn W, Hollak CE, Florquin S, van den Bergh Weerman MA, Wanner C, West ML, Biegstraaten M, Linthorst GE. Chronic kidney disease and an uncertain diagnosis of Fabry disease: approach to a correct diagnosis. Mol Genet Metab. 2015;114(2):242-247. https://doi.org/10.1016/j.ymgme.2014.08.007
  70. Thomas AS, Hughes DA. Fabry disease. Pediatr Endocrinol Rev. 2014;12 (suppl 1):88-101.
  71. El Dib RP, Nascimento P, Pastores GM. Enzyme replacement therapy for Anderson-Fabry disease. Cochrane Database Syst Rev. 2013;2:CD006663. https://doi.org/10.1002/14651858.CD006663.pub3
  72. Ghali J, Nicholls K, Denaro C, Sillence D, Chapman I, Goldblatt J, Thomas M, Fletcher J; Australian State Fabry Disease Treatment Centres. Effect of reduced agalsidase Beta dosage in fabry patients: the Australian experience. JIMD Rep. 2012;3:33-43. https://doi.org/10.1007/8904_2011_44
  73. Deegan PB. Fabry disease, enzyme replacement therapy and the significance of antibody responses. J Inherit Metab Dis. 2012;35(2):227-243. https://doi.org/10.1007/s10545-011-9400-y
  74. Lenders M, Karabul N, Duning T, Schmitz B, Schelleckes M, Mesters R, Hense HW, Beck M, Brand SM, Brand E. Thromboembolic events in Fabry disease and the impact of factor V Leiden. Neurology. 2015;84(10):1009-1016. https://doi.org/10.1212/WNL.0000000000001333
  75. Politei JM. Can we use statins to prevent stroke in Fabry disease? J Inherit Metab Dis. 2009;32(4):481-487. https://doi.org/10.1007/s10545-009-1156-2

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.